News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Results>HENGRUI PHARMA Sees 21.78% YoY Growth in 1Q NP Attributable to Shareholders
HENGRUI PHARMA (01276.HK) announced that its operating revenue for 1Q26 rose by 12.98% YoY to RMB8.141 billion, while net profit attributable to its shareholders increased by 21.78...
Reset
Send
The window will close in 5 seconds
<Results>HENGRUI PHARMA Sees 21.78% YoY Growth in 1Q NP Attributable to Shareholders
Close
Recommend
12
Positive
13
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!

HENGRUI PHARMA (01276.HK)  -0.650 (-0.979%)    Short selling $66.91M; Ratio 27.140%   announced that its operating revenue for 1Q26 rose by 12.98% YoY to RMB8.141 billion, while net profit attributable to its shareholders increased by 21.78% YoY to RMB2.282 billion, with basic EPS of RMB0.34.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25.)

Dividend History
Announce DateEventParticular
2026/03/26FinalD:RMB 0.2000 (Equivalent to approximately HKD 0.22828)
2025/10/273rd QuarterlyNo Dividend
2025/08/20InterimNo Dividend

Related News M Stanley: HENGRUI PHARMA (01276.HK) Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company (BMY.US) to Accelerate Globalization
Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.